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Since Ashford and Porter first discovered that cells “eat 
themselves” in 1962, the process known as autophagy has 
generated intense interest in both biomedical research and 
clinical medicine. Autophagy is a regulated cellular path-
way that transports damaged, modified or aging organelles 
and proteins to lysosomes/vacuoles for degradation. But 
recently, autophagy has been identified as being not only a 
widespread normal physiological process, but also a cell 
defense mechanism in response to an adverse cellular envi-
ronment, directly related to the pathological processes of 
clinical diseases, including cardiovascular disease, lung 
disease, cancer, neurodegenerative disease and infection. 
The role of autophagy in diseases can be either beneficial or 
harmful: normal levels of autophagy can protect cells from 
environmental stimuli; however, continued excessive or 
insufficient autophagy can lead to disease. The level of au-
tophagy may be reflective of the development of diseases 
and may provide a target for disease treatment. 
Autophagy is a lysosome-mediated, bulk degradative 
process by which eukaryotes recycle organelles and long- 
duration proteins. Based on the distinctive degradative 
mechanisms, autophagy is conventionally described in three 
main forms: (i) chaperone-mediated autophagy; (ii) micro-
autophagy; and (iii) macroautophagy [1]. Macroautophagy 
involves the formation of a dynamic subcellular organelle, a 
so-called “autophagosome”. Autophagosomes play a very 
important role in cell degradation and have a close relation-
ship with diseases of protein transport dysfunction and deg-
radation. A multivesicular body is another dynamic subcel-
lular organelle formed by invagination of the limited mem-
brane of a late endosome and is involved in various pro-
cesses including protein transport and sorting. Pashkova et 
al. [2] have discussed the assembly mechanisms, interac-
tions and functions of ESCRT complexes (the endosomal 
sorting complex required for transport) by ubiquitinated 
proteins and ubiquitination in multivesicular bodies. This 
research provides new information about protein transport 
and degradation in cells, and may provide links to some 
diseases in terms of abnormalities of protein degradation. 
The process of autophagy is well-regulated, and the pro-
tein kinase target of rapamycin, TOR, is a key inhibitory 
regulator. Under starvation conditions, or in the presence of 
rapamycin, TOR kinase is inactive and autophagic activity 
is enhanced. In response to insulin-like and other growth 
factor signals, the class I PI3K/Akt signaling molecules link 
receptor tyrosine kinases to activate TOR kinase and there-
by repress autophagy [3]. Class III phosphoinositide 
3-kinase (class III PI3K), which specifically phosphorylates 
PtdIns to generate PtdIns3P, combined with beclin1 to form 
a class III PI3K-Beclin1 complexes, also plays a vital role 
in autophagy and vacuolar sorting pathways [4]. 
Autophagy is not only a widespread normal physiologi-
cal process, but is also an important mechanism that assists 
cells in adapting to environmental change, provides a de-
fense against the invasion of pathogenic microorganisms 
and aids in the maintenance of homeostasis. Recently, it has 
been discovered that autophagy not only has an effect on 
cellular homeostasis but also has an effect on organs and is 
involved in the pathological processes of clinical disease. 
By having a function in disease, autophagy has become a 
target in some disease treatments, particularly in some car-
diovascular, neuronal, lung and metabolism diseases and in 
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tumor development and infection. 
1  Autophagy in cardiovascular disease 
Despite the ongoing advances in treatment options, cardio-
vascular disease remains a leading cause of death in China 
and is reaching pandemic scales worldwide. The dysfunc-
tion and loss of myocytes is key in the pathology of cardio-
vascular disease, particularly in terms of the cellular au-
tophagic pathway. It is well known that mitochondrial bal-
ance can maintain the function of myocytes. Therefore, se-
lective autophagy of mitochondria, termed “mitophagy”, 
plays a very important role in maintaining myocyte function 
[5]. Lizama-Manibusan et al. [6] has summarized that re-
dox-sensitive proteins regulate mitophagy and ultimately 
promote cell survival in diseases including Parkinson’s, 
Amyotrophic Lateral Sclerosis, and cancer. 
At present, the exact role of autophagy in the heart is 
highly debated, but it has been suggested to play a key role 
in regulating cell turnover in cardiomyopathies and heart 
failure. Xie et al. [7] surmised that dysfunctional myocardial 
autophagy contributes to a diverse set of heart diseases, 
such as Danon disease, myocardial hypertrophy and heart 
failure. Vascular endothelial cells (VEC) are one of the 
most active cells in the human body, and many cardiovas-
cular diseases are correlated with functional changes to 
VEC. For this reason, VEC autophagy is another target in 
the treatment of cardiovascular diseases, especially athero-
sclerosis. Epigallocatechin-gallate (EGCG) stimulates au-
tophagy in vascular endothelial cells and become a potential 
therapeutic reagent to prevent cardiovascular complications 
[8]. These reports suggest that autophagy in myocytes and 
VEC are crucial factors in cardiovascular disease. 
2  Autophagy in neurons 
In neurons, autophagy has been reported as being active in 
the acute phase after subarachnoid hemorrhage. The activa-
tion of autophagy decreased neuronal apoptosis and ame-
liorated early brain injury EBI after subarachnoid hemor-
rhage and may, therefore, be a potential effective target for 
preventing EBI after subarachnoid hemorrhage [9]. Endo-
plasmic reticulum (ER) stress-induced autophagy might 
contribute to the neuroprotective effect of brain ischemic 
preconditioning [10]. However, it has also been reported 
that hypertension can induce excessive autophagic activa-
tion in the brain, leading to cell death, and subsequently 
induce several disorders. Angiotensin-(1–7) exerts neuro-
protective effects by preventing hypertension-induced ex-
cessive autophagic activation, reducing oxidative stress and 
apoptosis in the brains of spontaneously hypertensive rats 
[11]. Autophagy vacuoles were also frequently observed in 
neurodegenerative diseases such as Alzheimer’s, Parkin-
son’s, and Huntington’s diseases as well as prion diseases. 
A large amount of data show that autophagy has a protec-
tive role in neurodegeneration: autophagy deficiency is a 
secondary disease mechanism in neurodegeneration and 
induction of autophagy can act therapeutically in neuro-
degenerative disorders [12]. Prion diseases, characterized by 
spongiform degeneration and the accumulation of misfolded 
and aggregated PrPSc in the central nervous system, are 
among the fatal neurodegenerative and infectious disorders 
in humans and animals. Autophagy mediates neuronal tox-
icity or serves a protective function in prion diseases, and 
some small molecules (such as lithium, rapamycin, Sirtuin 1 
and resveratrol) mitigate such diseases of brain function 
[13]. The above research suggests that autophagy can pro-
tect from neurodegeneration. The regulation of autophagy in 
neurons may counter the development of neurodegenerative 
diseases. 
3  Autophagy in cancer 
Autophagy is an evolutionarily conserved catabolic process 
crucial for cell death and survival, and also provides an im-
portant function in tumor development. Changes in macro-
autophagic activity have been described in cancer cells and 
in solid tumors, and inhibition of macroautophagy promotes 
tumorigenesis. Autophagy is emerging as an important bio-
logical mechanism in targeting human cancers, including 
cervical cancer [14], liver cancer [15], colorectal cancer 
[16], colon cancer [17], and prostate cancer [18] and au-
tophagy suppresses tumor progression by limiting genome 
instability, promotes tumor cell survival and restricts necro-
sis, inflammation, and tumorigenesis. 
4  Autophagy in lung disease 
Autophagy is closely related to the occurrence and deve- 
lopment of lung diseases, where its activity can fluctuate. 
Liu et al. [19] reported that the IL17A-PI3K-GSK3β-BCL2 
signaling pathway participates in the attenuation of au-
tophagic activity in lung epithelial cells, which is consi- 
dered to be primarily responsible for the development and 
progression of IL17A-induced pulmonary fibrosis. The 
downregulation of autophagy may lead to systemic inflam-
mation and acute lung injury following sepsis. The direct or 
indirect modification of autophagy using rapamycin resulted 
in improved survival. Enhancing or restoring autophagy 
early after sepsis seems to be a potential strategy for the 
treatment of sepsis-induced acute lung injury [20]. Yang et 
al. [21] draw the conclusion that there is a relationship be-
tween autophagy and lung diseases, including pulmonary 
emphysema, chronic obstructive pulmonary disease, lung 
cancer and pulmonary tuberculosis. This research helps in 
understanding the autophagic process, the regulation of au-
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tophagy in lung diseases, and provides new ideas for thera-
pies for lung diseases. 
5  Autophagy and pathogens 
Autophagy is associated with the formation of autophago-
somes, and further functions as a defense mechanism 
against infection by various pathogens. Lupfer et al. [22] 
reported that nucleotide-binding oligomerization domain 2 
receptor and receptor interacting protein kinase 2 signaling 
can protect against virally triggered immunopathology by 
negatively regulating activation of NOD like receptors fam-
ily, pyrin domain containing three inflammasomes and 
production of IL-18 via Unc-51-like kinase 1-dependent 
mitophagy. Some pathogens, such as Salmonella enterica 
serovar Typhimurium and Mycobacterium tuberculosis, 
succumb to autophagy and are transported to lysosomes for 
degradation, yet many pathogens, including human papil-
lomavirus (HPV)16 and oncolytic viruses, subvert this 
pathway, exploiting autophagy to their advantage. For ex-
ample, Ishii [23] found that autophagy is indeed induced 
during the HPV16 entry process, and oncolytic viruses per-
turb cellular autophagy machinery in infected tumor cells 
both in vitro and in vivo [24]. During Mycobacterium tu-
berculosis infection, autophagy acts not only as an antimi-
crobial mechanism for the clearance of intracellular patho-
gen, but also prevents excessive inflammation, preventing 
adverse effects on the host. Novel autophagy-based therapy 
is being considered as a better tuberculosis medication [25]. 
HIV protease inhibitors (PI) are core components of highly 
active anti-retroviral therapy, the most effective treatment 
for HIV infection currently available. However, HIV PIs 
have now been linked to lipodystrophy and dyslipidemia, 
which are major risk factors for cardiovascular disease and 
metabolic syndrome. Zha et al. [26] found that activation of 
ER stress and impairment of autophagy activity are in-
volved in HIV PI-induced dysregulation of lipid metabolism 
in adipocytes. The key components of ER stress and au-
tophagy signaling pathways are potential therapeutic targets 
for the HIV PI-induced metabolic side effects in HIV pa-
tients. Historically, influenza pandemics have arisen from 
avian influenza viruses. Avian influenza viruses H5N1 and 
H9N2 are potential pandemic candidates. It is reported that 
autophagic responses play a role in influenza virus-induced 
CXCL10 and interferon-α expression in primary human 
blood macrophages [27]. Accumulation of autophagosomes 
has also been observed in H5N1-infected lungs from a hu-
man cadaver, from mice, as well as in infected A549 human 
epithelial lung cells. H5N1 caused autophagic cell death 
through suppression of mTOR signaling [28]. Autophagic 
cell death of alveolar epithelial cells plays a crucial role in 
the high mortality rates of H5N1 infection. Autopha-
gy-blocking agents might be useful as prophylactics and 
therapeutics against human infection by the H5N1 virus 
[29]. An anti-influenza agent, human monoclonal ScFv, has 
anti-autophagic function [30]. Recently, a new avian influ-
enza virus, H7N9, emerged as a serious threat to humans. 
Further research into the role of autophagy in avian influ-
enza virus infection may provide new therapies to combat 
infection. 
6  Autophagy and metabolism 
Autophagy is a process for the degradation of proteins and 
organs. It therefore plays a role in the regulation of metabo-
lism in cells. Autophagy and lipid homeostasis (both ancient 
cellular pathways) have seemingly co-evolved to share 
common regulatory elements, and autophagy has emerged 
as a prominent mechanism involved in the regulation of 
lipid metabolism. Autophagy is involved in some diseases 
characterized by a dysregulation of lipid metabolism, such 
as obesity, diabetes and atherosclerosis [31]. Autophagy is 
required for adipocyte differentiation and the concurrent 
accumulation of lipid droplets, and it also affects lipid me-
tabolism through contributions to lipoprotein [32]. It is re-
ported that ketogenic amino acid replacement in food could 
be a novel strategy to combat hepatic steatosis and meta-
bolic abnormalities, possibly through induction of autopha-
gy [33]. It is also reported that obesity and excessive calorie 
intake are associated with the defective regulation of au-
tophagy in adipose tissue [34], and insulin resistance in ad-
ipose tissue of obese Ristar Ottawa Karlsburg W (RT1u) 
rats is associated with upregulation of differing autophagic 
markers in visceral and subcutaneous fat deposits [35]. 
MXL-3 and HLH-30 act as transcriptional switches cou-
pling lysosomal lipolysis and autophagy to nutrient availa-
bility and controlling fat storage and ageing in Caenorhab-
ditis elegans [36]. In obesity, autophagy helps maintain 
β-cell mass, structure and function; autophagy-deficient 
β-cells can handle basal metabolic stress but have problems 
dealing with increased metabolic stress [37]. These studies 
suggest that autophagy is a vital regulator of metabolic dis-
ease. 
7  Levels of autophagy for disease detection 
Normal levels of autophagy can protect cells from environ-
mental stimuli; however, continued excessive or insufficient 
autophagy can lead to disease. The level of autophagy may 
reflect the degree of some diseases, therefore detection of 
the level of autophagy may be an indirect way to evaluate 
some diseases. Dysfunction of autophagy involves for-
mation and degeneration of autophagosomes or the over- 
expression of some autophagy-related proteins. Accordingly, 
accurate and comprehensive evaluation of autophagy in-
cludes autophagosome detection, as well as the fluency of 
autophagic degeneration, for example, autophagic flux as-
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say. At present, transmission electron microscopy [38,39], 
immunofluorescence and immunoblotting techniques are 
commonly used to detect autophagy. However, these meth-
ods cannot describe the dynamic process of autophagy. 
More accurate detection methods are needed. Additionally, 
artificial up- or downregulation of autophagy by drugs (for 
example, autophagy inducers like rapamycin and inhibitors 
like 3-MA) or gene interferences in vitro (for example, 
RNA interfere Atg3, Atg5, Atg7 and Beclin1) and in vivo 
(for example, GFP-LC3 transgenic mice [40,41]) have also 
been considered as an important part of autophagy analysis. 
Any method used alone may not provide sufficient evidence 
of autophagy. Careful attention needs to be paid to the re-
sults of any assays for autophagy [42].  
8  Conclusion 
With its roles in cardiovascular disease, lung disease, cancer 
and viral infection, autophagy’s importance in disease initi-
ation and progression is just beginning to be understood. 
More researchers are turning their attention to the role of 
autophagy in disease treatment. Zou et al. [43] reported that 
colostrum contains a high level of miR-30a, and this 
miR-30a restrained autophagy activity while promoting 
apoptosis of HeLa cells induced by cis-DDP (cis-dichloride 
diamine platinum, cis-DDP, Pt(NH3)2Cl2). The miR-30a- 
rich fraction of colostrum also reduced tumor size more 
effectively than did treatment with DDP alone in mice. It is 
suggested that the miR-30a-rich fraction of colostrum can 
sensitize cancer cells to anti-cancer drugs, thus enhancing 
the effect of chemotherapeutic drugs during tumor treatment. 
Chen et al. [44] reported that miR-221/222 acts as a prom-
ising biomarker for breast cancer by regulating autophagy, 
and that it may offer a new way for molecular targeting in 
cancer treatment. These reports suggest that autophagy may 
become a target for cancer therapy in the future. It has been 
reported that rapamycin, an inducer of autophagy, can in-
hibit certain tumor cell growths, including rhabdomyosar-
coma, neuroblastoma, small-cell lung carcinoma, osteosar-
coma, pancreatic carcinoma, renal cell carcinoma, prostate 
cancer and breast cancer. Some rapamycin analogs, such as 
CCI-779/temsirolimus [45] and RAD-001/everoli- mus [46], 
have been used to treat tumors such as glioblastoma, pros-
tate cancer and breast cancer. Recent studies with omepra-
zole, which is commonly used in gastritis treatment, have 
found that it inhibits the growth of tumor cells by inducing 
autophagy and enhances the function of 5-fluor- ouracile 
[47]. Chloroquine, an inhibitor of autophagy, can enhance 
the function of imatinibmesylate in Philadelphia chromo-
some-positive cells and chronic myeloid leukemia treatment. 
Another autophagy inhibitor, bafilomycinA1, has the same 
role in chronic myeloid leukemia [48]. Xie et al. [7] have 
reported that some anti-tumor drugs (for example, doxoru-
bicine, daunorubicin, resveratrol, temozolomide, As2O3, 
gemcitabine and paclitaxel) and some cardiovascular regu-
lators (for example, angiotensin II, carvedilol and atorvas-
tatin) can induce autophagy, but it is not clear how best to 
regulate autophagy using these drugs or whether autophagy 
is indeed an appropriate target for these drugs in the treat-
ment of disease.  
It is becoming apparent that autophagy is not only a 
physiological phenomenon for cells, but could possibly be-
come a mechanism for the development of approaches in 
the treatment of disease. More biomedical scientists are 
turning their attention to this remarkable cellular process. 
Because autophagy is a dynamic and complex process, and 
the regulation of autophagy is complex, the level of au-
tophagy at a particular time and in a particular situation is 
very hard to detect. The role of autophagy in disease can be 
either beneficial or harmful. A more complete characteriza-
tion of the autophagic machinery needs to be described. 
Alongside gaining an understanding of the implications of 
autophagy in disease, future research will need to focus on 
how to use autophagy as a target in the treatment of diseases. 
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